For Osamu Tsukimori's latest contributions to The Japan Times, see below:
The key benefit of self-replicating vaccines is their efficiency, as they require only a fraction of the dosage of conventional vaccines to trigger a strong immune response.
The move comes after the U.S. Food and Drug Administration lowered the minimum age for the vaccine to 12 on May 10.
Doctors are gearing up for clinical trials of convalescent plasma therapy, but many overseas hospitals have already moved on to other remedies.
The formal approvals, following a health ministry panel's sign-off Thursday, mark a major step toward speeding up the nation's sluggish inoculation drive.
The approval marks an important milestone in increasing vaccine supplies as Prime Minister Yoshihide Suga aims to ramp up vaccinations to 1 million shots a day.
Four more states of emergency are likely at a pace of 220,000 jabs per day, while only one would be needed if 880,000 shots are given daily, scientists project.
The government is hoping to use Moderna Inc.’s COVID-19 shot once it is approved as it looks to quickly ramp up the vaccine rollout amid signs of an explosive rise in new variant cases.
Obtaining vast amounts of ammonia is key to the 2050 emissions goal, but procuring only so-called green ammonia produced using renewable energy will be difficult.
The Japanese government announced on Monday that it has so far detected a total 21 cases of the Indian variant, including 20 cases confirmed via airport quarantine.
Climate Action Tracker analysis shows that Japan needs to reduce emissions by 62% by 2030 from 2013 levels to meet Paris Agreement targets.
